MARKET

MLTX

MLTX

MoonLake Immunotherapeutics
NASDAQ
14.32
-0.47
-3.18%
After Hours: 14.32 0 0.00% 17:29 12/15 EST
OPEN
14.79
PREV CLOSE
14.79
HIGH
14.79
LOW
14.29
VOLUME
1.36M
TURNOVER
--
52 WEEK HIGH
62.75
52 WEEK LOW
5.95
MARKET CAP
1.02B
P/E (TTM)
-4.3033
1D
5D
1M
3M
1Y
5Y
1D
MoonLake Immunotherapeutics Faces Securities Fraud Class Action
Reuters · 10h ago
Weekly Report: what happened at MLTX last week (1208-1212)?
Weekly Report · 14h ago
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
Barchart · 14h ago
Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Barchart · 3d ago
MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Securities Fraud Allegations
Reuters · 3d ago
MoonLake Immunotherapeutics Class Action: Levi & Korsinsky Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX
Barchart · 3d ago
DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025
Barchart · 4d ago
Top Executives Cash In on MoonLake Immunotherapeutics Stock!
TipRanks · 4d ago
More
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Webull offers MoonLake Immunotherapeutics stock information, including NASDAQ: MLTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MLTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MLTX stock methods without spending real money on the virtual paper trading platform.